Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study.

被引：0
|
作者：
Dasari, Arvind
Tabernero, Josep
Garcia-Carbonero, Rocio
Elez, Elena
Yoshino, Takayuki
Sobrero, Alberto F.
Yao, James C.
Garcia-Alfonso, Pilar
Kocsis, Judit
Cubillo Gracian, Antonio
Sartore-Bianchi, Andrea
Satoh, Taroh
Randrian, Violaine
Tomasek, Jiri
Chong, Geoff
Paulson, Andrew Scott
Wu, Liwen
Chen, Lucy F.
Eng, Cathy
机构：
[1] Veneto Inst Oncol IOV IRCCS, Padua, Italy
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Vall Hebron Inst Oncol, Barcelona, Spain
[4] UCM, Hosp Univ 12 Octubre Imas12, Madrid, Spain
[5] Natl Canc Ctr Hosp East Kashiwa, Kashiwa, Japan
[6] Azienda Ospedaliera Univ San Martino, Genoa, Italy
[7] Univ Complutense, Hosp Gen Univ Gregorio Maranon, IiSGM, Madrid, Spain
[8] Bacs Kiskun Megye Oktatokorhaz, Kecskemet, Hungary
[9] HM Univ Madrid Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain
[10] Univ Milan, Milan, Italy
[11] Osaka Univ, Grad Sch Med, Suita, Japan
[12] Univ Poitiers Hosp, Poitiers, France
[13] Masaryk Mem Canc Inst, Brno, Czech Republic
[14] Austin Hosp, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Vic, Australia
[15] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[16] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[17] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.171
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [1] Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2
    Eng, Cathy
    Dasari, Arvind
    Lonardi, Sara
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto
    Yao, James
    Garcia-Alfonso, Pilar
    Kocsis, Judit
    Gracian, Antonio Cubillo
    Sartore-Bianchi, Andrea
    Satoh, Taroh
    Randrian, Violaine
    Tomasek, Jiri
    Chong, Geoff
    Yang, Zhao
    Guevara, Ferdinand
    Schelman, William
    Pallai, Rajash
    Tabernero, Josep
    ONCOLOGIST, 2025, 30 (03):
  • [2] Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
    Dasari, Arvind
    Lonardi, Sara
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto
    Yao, James
    Garcia-Alfonso, Pilar
    Kocsis, Judit
    Gracian, Antonio Cubillo
    Sartore-Bianchi, Andrea
    Satoh, Taroh
    Randrian, Violaine
    Tomasek, Jiri
    Chong, Geoff
    Paulson, Andrew Scott
    Masuishi, Toshiki
    Jones, Jeremy
    Csoszi, Tibor
    Cremolini, Chiara
    Ghiringhelli, Francois
    Shergill, Ardaman
    Hochster, Howard S.
    Krauss, John
    Bassam, Ali
    Ducreux, Michel
    Elme, Anneli
    Faugeras, Laurence
    Kasper, Stefan
    Van Cutsem, Eric
    Arnold, Dirk
    Nanda, Shivani
    Yang, Zhao
    Schelman, William R.
    Kania, Marek
    Tabernero, Josep
    Eng, Cathy
    LANCET, 2023, 402 (10395): : 41 - 53
  • [3] Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study.
    Kasper, Stefan
    Sartore-Bianchi, Andrea
    Randrian, Violaine
    Cremolini, Chiara
    Arnold, Dirk
    Dasari, Arvind
    Eng, Cathy
    Lonardi, Sara
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto F.
    Yao, James C.
    Hochster, Howard S.
    Van Cutsem, Eric
    Tougeron, David
    Yu, Ziji
    Dong, Cynthia
    Schelman, William R.
    Ghiringhelli, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 142 - 142
  • [4] Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
    Elez Fernandez, M. E.
    Dasari, N. A.
    Lonardi, S.
    Eng, C.
    Garcia-Carbonero, R.
    Yoshino, T.
    Sobrero, A.
    Yao, J. C.
    Garcia Alfonso, P.
    Kocsis, J.
    Cubillo Gracian, A.
    Sartore Bianchi, A.
    Satoh, T.
    Randrian, V.
    Cremolini, C.
    Yang, Z.
    Schelman, W.
    Zhu, H.
    Chen, L.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S442 - S443
  • [5] Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2
    Bekaii-Saab, Tanios S.
    Dasari, Arvind
    Eng, Cathy
    Lonardi, Sara
    Yoshino, Takayuki
    Sobrero, Alberto F.
    Yao, James C.
    Garcia-Alfonso, Pilar
    Sartore-Bianchi, Andrea
    Hochster, Howard S.
    Hubbard, Joleen M.
    Price, Timothy Jay
    Tougeron, David
    Qin, Shukui
    Li, Jin
    Schelman, William R.
    Fan, Songhua
    Yu, Ziji
    Chen, Lucy F.
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer
    Dasari, Arvind
    Sobrero, Alberto
    Yao, James
    Yoshino, Takayuki
    Schelman, William
    Yang, Zhao
    Chien, Caly
    Kania, Marek
    Tabernero, Josep
    Eng, Cathy
    FUTURE ONCOLOGY, 2021, 17 (24) : 3151 - 3162
  • [7] FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
    Dasari, Arvind
    Yao, James C.
    Sobrero, Alberto F.
    Yoshino, Takayuki
    Schelman, William R.
    Nanda, Shivani
    Chien, Caly
    Pu, Su-Fen
    Kania, Marek K.
    Tabernero, Josep
    Eng, Cathy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [8] Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
    Li, Jin
    Qin, Shukui
    Xu, Rui-Hua
    Shen, Lin
    Xu, Jianming
    Bai, Yuxian
    Yang, Lei
    Deng, Yanhong
    Chen, Zhen-dong
    Zhong, Haijun
    Pan, Hongming
    Guo, Weijian
    Shu, Yongqian
    Yuan, Ying
    Zhou, Jianfeng
    Xu, Nong
    Liu, Tianshu
    Ma, Dong
    Wu, Changping
    Cheng, Ying
    Chen, Donghui
    Li, Wei
    Sun, Sanyuan
    Yu, Zhuang
    Cao, Peiguo
    Chen, Haihui
    Wang, Jiejun
    Wang, Shubin
    Wang, Hongbing
    Fan, Songhua
    Hua, Ye
    Su, Weiguo
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (24): : 2486 - 2496
  • [9] Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 trial
    Garcia-Carbonero, R.
    Dasari, N. A.
    Eng, C.
    Tabernero, J.
    Yoshino, T.
    Hochster, H.
    Arnold, D.
    Randrian, V.
    Schelman, W.
    Dong, L.
    Yu, Z.
    Chen, L.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S439 - S439
  • [10] Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study
    Sobrero, Alberto
    Dasari, Arvind
    Aquino, Jeneth
    Lonardi, Sara
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Yao, James
    Garcia-Alfonso, Pilar
    Kocsis, Judit
    Gracian, Antonio Cubillo
    Sartore-Bianchi, Andrea
    Satoh, Taroh
    Randrian, Violaine
    Tomasek, Jiri
    Chong, Geoff
    Price, Timothy
    Yu, Ziji
    Geiger, Ashley
    Chen, Lucy
    Yang, Zhao
    Schelman, William R.
    Kania, Marek
    Tabernero, Josep
    Eng, Cathy
    EUROPEAN JOURNAL OF CANCER, 2025, 218
12345